INTRODUCTION: In several malignant diseases, elevated heme oxygenase-1 (HO-1) is associated with progression or resistance to chemotherapy. We evaluated the clinical significance of HO-1 expression in non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We examined 109 patients with non-muscle-invasive bladder cancer. The immunoexpression of HO-1, p53, and Ki-67 was analyzed using paraffin-embedded tissue from transurethral resection in comparison with the clinicopathological variables. RESULTS: Positive expression of HO-1 was found in 66 of 109 tumors (61%), and the positivity of HO-1 correlated significantly with high tumor grade and the altered expression patterns of p53 and Ki-67. In our analysis of 16 cases treated by intravesical administration of anthracyclines, the positive expression of HO-1 correlated with poor disease-free survival (p = 0.015). In in vitro experiments using urothelial cancer cell lines, HO-1 upregulation was observed by exposure to doxorubicin. Moreover, siRNA-mediated suppression of HO-1 upregulation sensitized the urothelial cancer cells to doxorubicin. CONCLUSIONS: Our findings suggested that resistance against anthracyclines correlated with HO-1 and expression analysis of HO-1 may be a useful predictive marker for intravesical administration of anthracyclines.
INTRODUCTION: In several malignant diseases, elevated heme oxygenase-1 (HO-1) is associated with progression or resistance to chemotherapy. We evaluated the clinical significance of HO-1 expression in non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We examined 109 patients with non-muscle-invasive bladder cancer. The immunoexpression of HO-1, p53, and Ki-67 was analyzed using paraffin-embedded tissue from transurethral resection in comparison with the clinicopathological variables. RESULTS: Positive expression of HO-1 was found in 66 of 109 tumors (61%), and the positivity of HO-1 correlated significantly with high tumor grade and the altered expression patterns of p53 and Ki-67. In our analysis of 16 cases treated by intravesical administration of anthracyclines, the positive expression of HO-1 correlated with poor disease-free survival (p = 0.015). In in vitro experiments using urothelial cancer cell lines, HO-1 upregulation was observed by exposure to doxorubicin. Moreover, siRNA-mediated suppression of HO-1 upregulation sensitized the urothelial cancer cells to doxorubicin. CONCLUSIONS: Our findings suggested that resistance against anthracyclines correlated with HO-1 and expression analysis of HO-1 may be a useful predictive marker for intravesical administration of anthracyclines.
Authors: S Kongpetch; A Puapairoj; C K Ong; L Senggunprai; A Prawan; U Kukongviriyapan; W Chan-On; E Y Siew; N Khuntikeo; B T Teh; V Kukongviriyapan Journal: Cell Prolif Date: 2016-01-04 Impact factor: 6.831
Authors: Norberto A Gandini; María E Fermento; Débora G Salomón; Diego J Obiol; Nancy C Andrés; Jean C Zenklusen; Julián Arevalo; Jorge Blasco; Alejandro López Romero; María M Facchinetti; Alejandro C Curino Journal: Tumour Biol Date: 2014-03
Authors: Magdalena Kozakowska; Barbara Dobrowolska-Glazar; Krzysztof Okoń; Alicja Józkowicz; Zygmunt Dobrowolski; Józef Dulak Journal: J Clin Med Date: 2016-02-25 Impact factor: 4.241
Authors: A L Furfaro; N Traverso; C Domenicotti; S Piras; L Moretta; U M Marinari; M A Pronzato; M Nitti Journal: Oxid Med Cell Longev Date: 2015-11-30 Impact factor: 6.543